AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16337461
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 200 microg once daily
Trial: 16337461
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg 3 times daily
Trial: 14988337
Drug: Intravenous adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous adrenaline (epinephrine)
Trial: 12520835
Drug: High-dose adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adrenaline
Trial: 2794177
Drug: Structural family
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structural family therapy
Trial: 2794177
Drug: Psychodynamic child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic child therapy
Trial: 117789
Drug: Oral (Milk)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (Milk) feeding
Trial: 31522922
Drug: Subsidized community-supported
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subsidized community-supported agriculture membership (weekly farm produce pickup from June to November)
Trial: 25851629
Drug: CYT107 before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYT107 before chemotherapy
Trial: 25851629
Drug: CYT107 during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYT107 during chemotherapy
Trial: 25851629
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before chemotherapy
Trial: 25851629
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during chemotherapy
Trial: 23547623
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate solution (CHO) given in the evening prior to surgery and 2-3 hours before anesthesia.
Trial: 11386854
Drug: 5-hydroxytryptophan (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (4-6 mg/kg) and carbidopa (0.5-1.0 mg/kg)
Trial: 11386854
Drug: l-tryptophan (50-70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-tryptophan (50-70 mg/kg)
Trial: 11386854
Drug: 5-hydroxytryptophan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (1 mg/kg)
Trial: 8273320
Drug: Dulcolax suppository
RxNorm normalized name: bisacodyl Rectal Suppository [Dulcolax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulcolax suppository
Trial: 24768116
Drug: COP velocity
RxNorm normalized name: COP 1
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COP velocity and ML displacement
Trial: 22343600
Drug: Pressure-relieving suspension
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-relieving suspension boot (Heelift; DM Systems Inc, Evanston, Illinois)
Trial: 22343600
Drug: Intravenous bags
RxNorm normalized name: BAG
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bags
Trial: 16767414
Drug: Pergolide (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (0.075 mg)
Trial: 10955373
Drug: NK-104 2
RxNorm normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104 2 mg/day
Trial: 10955373
Drug: NK-104 4
RxNorm normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104 4 mg/day
Trial: 8617706
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/day titrated to 200 mg/day
Trial: 26987818
Drug: Behavioural change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural change programme (BCP) with ongoing active reinforcement and enhanced provision of moisturising cream
Trial: 15361263
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluoxetine for 8 weeks
Trial: 10362441
Drug: Metrifonate 50
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate 50 mg once daily
Trial: 8808221
Drug: 1.75 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.75 mmol/l calcium dialysate
Trial: 8808221
Drug: 1.25 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mmol/l calcium dialysate
Trial: 2020143
Drug: Cardioplegic solution
RxNorm normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardioplegic solution (Bretschneider) in Group A
Trial: 26683683
Drug: Blinatumomab (9-μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (9-μg/day continuous i.v. infusion on days 1-7 and 28-μg/day continuous i.v. infusion on days 8-28 for Cycle 1; subsequent cycles 28-μg/day continuous i.v. infusion on days 1-28)
Trial: 25054594
Drug: Weekly interdisciplinary
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly interdisciplinary program (WIP) consisting of educational activities, physical therapy, stretching, ergonomics, posture guidance, cognitive behavioral strategies.
Trial: 22209391
Drug: Everolimus 10mg
RxNorm normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 10mg once daily (1 previous VEGFr-TKI)
Trial: 22209391
Drug: Everolimus 10mg
RxNorm normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 10mg once daily (2 previous VEGFr-TKI)
Trial: 15507793
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin daily for 6 weeks
Trial: 7917695
Drug: Prophylactic medication
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic medication (pirenzepine)
Trial: 7917695
Drug: Prophylactic medication
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic medication (famotidine)
Trial: 7917695
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment (either pirenzepine or famotidine)
Trial: 7917695
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (first 36 patients without prophylactic medication)
Trial: 3126637
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) patch 5 mg/24 hours
Trial: 3126637
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) patch 10 mg/24 hours
Trial: 28360247
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly aerobic exercise training (AT) for 6 months
Trial: 28360247
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly aerobic exercise training (AT)
Trial: 19220089
Drug: Intravenous pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentoxifylline (500 mg in 500 mL saline for 2 hours followed by 700 mg in 1000 mL saline for 6 hours)
Trial: 19220089
Drug: Placebo (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1500 mL saline)
Trial: 15176496
Drug: Orally inhaled
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally inhaled fluticasone propionate (FP) 88 or 220 microg via metered-dose inhaler (MDI)
Trial: 15176496
Drug: Orally inhaled
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally inhaled fluticasone propionate (FP) 250 microg via Diskus
Trial: 15176496
Drug: Orally inhaled
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally inhaled fluticasone propionate (FP) 250 microg/salmeterol 50 microg via Diskus
Trial: 10404811
Drug: Transdermal 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta-estradiol (50 microg) for 6 weeks
Trial: 10404811
Drug: Estradiol in
RxNorm normalized name: estradiol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol in combination with oral norethisterone (1 mg) for 6 weeks
Trial: 10404811
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patches for 6 weeks
Trial: 10404811
Drug: Matching oral
RxNorm normalized name: By Ache Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo preparation for 6 weeks
Trial: 7564870
Drug: Omeprazole (OM)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole (OM) 20 mg mane
Trial: 7564870
Drug: Ranitidine (RAN)
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine (RAN) 300 mg nocte
Trial: 2406538
Drug: Fructose 1,6-diphosphate
RxNorm normalized name: fructose 1,6-diphosphate
DrugBank: Fosfructose (DB13863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose 1,6-diphosphate (FDP) infusion (250 mg.kg-1 body weight)
Trial: 6111083
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pindolol combined with 5 mg clopamide
Trial: 6111083
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg metoprolol combined with 12.5 mg hydrochlorothiazide
Trial: 31986288
Drug: Potassium chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium chloride (KCl) infusion at rates of 9.4 mmol/h, 12 mmol/h, or 15 mmol/h
Trial: 28587952
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 60mg loading dose at admission, followed by 20mg three times a day
Trial: 27354782
Drug: Glycopyrrolate 15.6
RxNorm normalized name: GLYCOPYRROLATE 15.6MCG CAP,INHL,60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 15.6 µg
Trial: 21733320
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg cholecalciferol per day
Trial: 17852442
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy with DFP at 75 mg/kg/day for 4 days/week and DFO at 40 mg/kg/day for 5-7 nights/week
Trial: 17852442
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy with DFP and DFO
Trial: 15024929
Drug: Observed single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observed single low-dose mefloquine (15 mg/kg) and artesunate (4 mg/kg)
Trial: 15024929
Drug: Observed single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observed single high-dose mefloquine (25 mg/kg) and artesunate (4 mg/kg)
Trial: 15024929
Drug: Observed artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Observed artesunate 4 mg/kg on day 0 plus self-administered mefloquine 15 mg/kg on day 1 and 10 mg/kg on day 2 with artesunate 4 mg/kg/day on day 1 and 2
Trial: 15024929
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose treatments
Trial: 8005188
Drug: Intravenous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous terbutaline sulphate
Trial: 7586920
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline
Trial: 8005188
Drug: Intravenous enprofylline
RxNorm normalized name: etofylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enprofylline
Trial: 31345135
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment (IAT) with NCCT ASPECTS 7 to 10
Trial: 31345135
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment (IAT) with NCCT ASPECTS 0 to 6
Trial: 31345135
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment (IAT) with NCCT ASPECTS
Trial: 31345135
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment (IAT) with diffusion weighted imaging ASPECTS
Trial: 27808530
Drug: Direct cause
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct cause statements (e.g., 'makes', 'increases')
Trial: 27808530
Drug: Can cause
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Can cause statements (e.g., 'can make', 'can increase')
Trial: 27808530
Drug: Moderate cause
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate cause statements (e.g., 'might cause', 'linked', 'associated with')
Trial: 24060195
Drug: Therapist-aided exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-aided exposure therapy
Trial: 12195755
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of pregnancy during breast cancer treatment
Trial: 12195755
Drug: Potentially curative
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially curative therapies administered during pregnancy
Trial: 12195755
Drug: Pregnancy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnancy after treatment for breast cancer
Trial: 11477817
Drug: Embolism chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embolism chemotherapy (ECT)
Trial: 11477817
Drug: Embolism chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embolism chemotherapy (ECT) + immunotherapy
Trial: 11477817
Drug: Embolism chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embolism chemotherapy (ECT) + Chinese herbal medicine
Trial: 8017869
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interferon-beta 1b
Trial: 31188734
Drug: GnRH Agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH Agonist
Trial: 31188734
Drug: GnRH Antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH Antagonist
Trial: 21668425
Drug: Narrowband ultraviolet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband ultraviolet B (NB‐UVB) phototherapy, 210 mJ cm(‐2) starting dose, increased by 10% each time, administered three times per week for 6 weeks.
Trial: 11390337
Drug: Immunoadsorption (IA)
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoadsorption (IA) therapy and subsequent immunoglobulin (IgG) substitution
Trial: 8304047
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin (200 IU/day, two times)
Trial: 3461385
Drug: Single 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 600 mg dose of trimethoprim
Trial: 22417905
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (5%)
Trial: 18226326
Drug: Ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10/20 mg combination tablet (EZE/SIMVA)
Trial: 18226326
Drug: Doubling statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling statin dose
Trial: 14517196
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg once daily for mild hepatic insufficiency patients
Trial: 14517196
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg every-other-day for moderate hepatic insufficiency patients
Trial: 14517196
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous doses of etoricoxib for both mild and moderate hepatic insufficiency patients
Trial: 8477136
Drug: PCA +
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA + CI (Patient-Controlled Analgesia plus Continuous Infusion)
Trial: 27468541
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with basic treatment
Trial: 27544742
Drug: Optimal Medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical Therapy (OMT) achieved group (548 patients, 18.2%)
Trial: 27544742
Drug: Non-Optimal Medical
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Optimal Medical Therapy (non-OMT) group (2,456 patients)
Trial: 27544742
Drug: Optimal Medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical Therapy (OMT) achieved group
Trial: 27544742
Drug: Non-Optimal Medical
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Optimal Medical Therapy (non-OMT) group
Trial: 24362587
Drug: HBO and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBO and intranasal mometasone furoate (10 μl/day)
Trial: 24362587
Drug: HBO and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBO and diclofenac sodium (10 mg/kg/day ip)
Trial: 7697841
Drug: Hirulog 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirulog 0.5 mg/kg per hour for 12 hours followed by 0.1 mg/kg per hour
Trial: 7697841
Drug: Hirulog 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirulog 1.0 mg/kg per hour for 12 hours followed by placebo
Trial: 7697841
Drug: Heparin 5000
RxNorm normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5000 U bolus followed by 1000 U/h titrated to an aPTT 2 to 2.5 times control after 12 hours
Trial: 9140320
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) given immediately after verapamil 80 mg (conventional formulation)
Trial: 9140320
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) given 2 hours after verapamil 80 mg (conventional formulation)
Trial: 9140320
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) given immediately after verapamil 240 mg (slow-release formulation)
Trial: 9140320
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) given 2 hours after verapamil 240 mg (slow-release formulation)
Trial: 9140320
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) given 4 hours after verapamil 240 mg (slow-release formulation)
Trial: 3904433
Drug: isoxicam (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isoxicam (200 to 400 mg per day, then reduced to 200 mg per day)
Trial: 23861093
Drug: Parent alliance
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent alliance with therapist in Family-Based Treatment (FBT)
Trial: 22480146
Drug: Adjuvant insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant insulin therapy
Trial: 17313718
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) 3 x 4 g/d for 6 months
Trial: 11533794
Drug: Ketotifen (0.13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (0.13 mg/kg body wt) with Chloroquine
Trial: 11533794
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Chloroquine, Ketotifen, and Fansidar
Trial: 9107182
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus aspirin (325 mg/d)
Trial: 1526054
Drug: Blocks of
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocks of the infraorbital, infratrochlear and external nasal nerves by intranasal infiltration
Trial: 2861067
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nebulized fenoterol (group A)